The role of tonsillectomy in the Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis syndrome; a literature review

BMC Ear, Nose and Throat Disorders

Jostein Førsvoll

 and

Knut Øymar

BMC Ear, Nose and Throat DisordersBMC series – open, inclusive and trusted201818:3

https://doi.org/10.1186/s12901-017-0049-5

©  The Author(s). 2018

Open Peer Review reports

Abstract

Background

Tonsillectomy (TE) or adenotonsillectomy (ATE) may have a beneficial effect on the clinical course in children with the Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis (PFAPA) syndrome. However, an immunological reason for this effect remains unknown. This literature review summarizes the current knowledge of the effect of TE or ATE in the PFAPA syndrome.

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis

REVIEW

          

• Abstract
• Metrics
• Get Permission

Authors Eshtiaghi P, Gooderham MJ

Published 23 February 2018 Volume 2018:13 Pages 13—20

DOI https://doi.org/10.2147/CE.S133661

Video abstract presented by Melinda J Gooderham

Views: 3

Panteha Eshtiaghi,¹ Melinda J Gooderham<sup>2–4

1</sup>Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; ²SKiN Centre for Dermatology, Peterborough, ON, Canada; ³Probity Medical Research, Waterloo, ON, Canada; ⁴Queen’s University, Kingston, ON, Canada

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant T_H2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited.

Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use

Open Access

Pharmaceutics 2018, 10(1), 24; doi:10.3390/pharmaceutics10010024

Ousama Rachid 1,*, Mutasem Rawas-Qalaji 2,* and Keith J. Simons 3

Abstract

: 

Epinephrine is a life-saving treatment in anaphylaxis. In community settings, a first-aid dose of epinephrine is injected from an auto-injector (EAI). Needle phobia highly contributes to EAI underuse, leading to fatalities—especially in children. A novel rapidly-disintegrating sublingual tablet (RDST) of epinephrine was developed in our laboratory as a potential alternative dosage form.

CSACI position statement: prescribing sublingual immunotherapy tablets for aeroallergens

Allergy, Asthma & Clinical Immunology Review Open Access

J. Quirt,

R. Gagnon,

A. K. Ellis and

H. L. Kim

• Email author

Allergy, Asthma & Clinical Immunology201814:1

https://doi.org/10.1186/s13223-017-0225-6

Background: Allergic rhinitis is estimated to affect 20–25% of Canadians and has a significant impact on quality of life, with many patients reporting inadequate control of their symptoms [1]. Mainstays of treatment for allergic rhinitis include avoidance, intranasal steroids, oral antihistamines and leukotriene receptor antagonists [2]. Specific immunotherapy offers disease-modifying treatment for those uncontrolled by, intolerant to, or averse to pharmacotherapy [3]. 

Heterogeneous pattern of differences in respiratory parameters between elderly with either good or poor FEV1

BMC Pulmonary Medicine

Research article

Open Access

Open Peer Review

• Stefan KarraschEmail author,
• Jürgen Behr,
• Rudolf M. Huber,
• Dennis Nowak,
• Annette Peters,
• Stefan Peters,
• Rolf Holle,
• Rudolf A. Jörres,
• Holger Schulz and
• KORA Study Group

BMC Pulmonary MedicineBMC series – open, inclusive and trusted201818:27

https://doi.org/10.1186/s12890-018-0582-z

Open Peer Review reports

Abstract

Background: The relationship of spirometric values to other respiratory and functional parameters in advanced age is not well studied.

Dr. Jay Portnoy describes how to perform a systematic review to answer questions

ACAAICOLA

Dr. Sharon Jacob discusses pediatric contact dermatitis

ACAAICOLA

Optimal control of asthma improved eosinophilic otitis media

Hypothesis & Experience  Open Access

---

       

Asia Pac Allergy. 2018 Jan;8(1):e5. English. Published online Jan 24, 2018.  https://doi.org/10.5415/apallergy.2018.8.e5

Yukako Seo,1 Manabu Nonaka,1 Yukie Yamamura,1 Ruby Pawankar,2 and Etsuko Tagaya3

1Department of Otolaryngology, Tokyo Women’s Medical University, Tokyo 162-8666, Japan.

2Department of Pediatrics, Nippon Medical School, Tokyo 113-0022, Japan.

3First Department of Medicine, Tokyo Women’s Medical University, Tokyo 162-8666, Japan.

Correspondence to: Manabu Nonaka. Department of Otolaryngology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. Tel: +81-3-3353-8111 (ext. 28531), Fax: +81-3-5269-7617, Email: nonaka-m@twmu.ac.jp

Abstract

Background Eosinophilic otitis media (EOM) is often associated with comorbid asthma. The middle ear cavity is part of the upper airway. Therefore, EOM and asthma can be considered to be a crucial part of the “one airway, one disease” phenomenon. Based on the concept of one airway, one disease in the context of allergic rhinitis and asthma, optimal level of inhalation therapy for better asthma control leads to improvement in allergic rhinitis.